Overview

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of hepatic impairment on rivipansel PK and safety.
Phase:
Phase 1
Details
Lead Sponsor:
GlycoMimetics Incorporated
Pfizer